Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients

University Hospital, Clermont-Ferrand90 enrolled

Overview

This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Cancer, Lung Colon Neoplasm Neuropathy;Peripheral

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or * Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles. Exclusion Criteria: * Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.), * History of stroke, * Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100), * Pain (NRS ≥ 4/10), * Pregnant or breastfeeding women, * Patients under guardianship, curatorship, deprived of liberty, or under legal protection

Outcomes

Primary Outcomes

Blood concentrations of microRNAs and severity score of sensory chemotherapy-induced peripheral neuropathy

Concentrations of microRNAs will be assessed in plasma, and severity score of sensory chemotherapy-induced peripheral neuropathy will be assessed using the QLQ-CIPN20 questionnaire.